Development, Characterization and Comparative Phar-macokinetic Evaluation of Ritonavir Nanosuspension, with a Model Nanoemulsion and Coarse Suspension for Improved Oral Delivery
DOI:
https://doi.org/10.37285/ijpsn.2021.14.3.3Abstract
Ritonavir (RV) is an antiretroviral drug, classified as BCS class II pharmaceutical active.It has limited bioavailability due to poor aqueous solubility and first pass metabolism. The purpose of this investigation was to develop optimal nanosuspension and to compare with a model nanoemulsion of RV for improved oral delivery. DSC studies showed good compatibility of excipients with drug. Nanosuspension was prepared by high pressure homogenization, while nanoemulsion was prepared by hot homogenization followed by ultrasonication. All prepared RV formulations were characterized and optimal system was selected and in vivo evaluated. Nanosuspension (F1) formulation containing 0.5% SLS showed homogeneity with least particle size was optimized and compared with coarse (powder) suspension. SEM studies on lyophilized nanosuspension revealed the absence of needle shaped drug crystals, indicating the loss of crystallinity. Prepared a model lipid nanoemulsion. It was having the size, PDI, ZP, EE and assay of 193.14 ± 12.66nm, 0.311 ± 0.04, -27.6 ± 1.184mV, 90.79 ± 0.319% and 99.57 ± 1.25% respectively. Next, a comparative pharmacokinetic study of RV nanosuspenison with respect to lipid nanoemulsion and coarse suspension was performed in male wistar rats. The Cmax of nanosuspension was significantly more when compared to that of NE or coarse drug suspension. The tmax was similar in case of both nanodelivery systems and significantly less when compared to that of coarse suspension. About 1.36 and 1.27 fold improvements in relative bioavailability (BA) of ritonavir via lipid nanoemulsion and nanosuspension were found when compared to coarse suspension. The study results revealed nominal but nonsignificant difference in oral bioavailability for the two nanodelivery systems. Taken together, this study confirmed the potential of nanosuspension and nanoemulsion systems in improving the bioavailability of ritonavir.
Downloads
Metrics
Keywords:
Ritonavir, antiviral, nanosuspension, nanoemulsion, dissolution, comparative bioavailability
Downloads
Published
How to Cite
Issue
Section
References
Alptug K, Nevin C and Zeynep ST (2016). Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach. Eur. J Pharm. Sci. 95:111-121.
Alptug K, Zeynep ST, Hakan E and Nevin C (2019). Evaluation of improved oral bioavailability of ritonavir nanosuspension. Eur. J. Pharm. Sci. 131: 153-158.
Amani AA, York P, Chrystyn H, Clark BJ and Do DQ (2008). Determination of factors controlling particle size in nanoemulsions using Artificial Neural Networks. Eur. J. Pharm. Sci. 35: 42-51.
Arun B, Narendar D and Kishan V (2018). Development of olmesartan medoxomil lipid based nanoparticles and nano-suspension: Preparation, characterization and comparative pharmacokinetic evaluation. Artif. Cells. Nanomed. Biotechnol. 46(1): 126-137.
Barry M, Gibbons S, Back D and Mulcahy F (1997). Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32(3): 194-209.
Bokai L, Weibin Z, Yun W, Cong W., Elaine JS, Xuan W, Fang J, GuangjiW, Luyong Z and Huiping Z (2010). Development of a novel self micro-emulsifying drug delivery system (SMEDDS) for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction. Mol Pharm. 7(3): 844–853.
Chiranjeevi K, Channabasavaraj KP, Lakshminarayana B and Kalyankumar B (2011). Development and validation of RP-HPLC method for quantitative estimation of ritonavir in bulk and pharmaceutical dosage forms. Int. J. Pharm. Sci. Res. 2(2): 336-340.
Deshmukh A and Kulkarni S (2014). Solid self-microemulsifying drug delivery system of ritonavir. Drug Dev. Ind. Pharm. 40(4): 477-87.
Gladys EG, Chandrasekharan R and Gordon LA (2005). Dissolution and Solubility behaviour of Fenofibrate in Sodium Lauryl Sulfate Solutions.Drug Dev. Ind. Pharm. 31: 917–922.
Harikrishna D, Svitlana S, Feng Z, Jessica M, Galina G, Albert O and Ismael JH (2013). Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs. J. Pharm. Sci. 102: 3808–3815.
Hsu A, Granneman GR and Bertz RJ (1998). Ritonavir clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 35(4): 275-91.
Javan F, Vatanara A, Azadmanesh K, Nabi-Meibodi M and Shakouri M (2017). Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles. J. Pharm. Pharmacol. 69(8): 1002-1009.
Jia L, Wong H, Cerna C and Steve DW (2002). Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res. 19(8): 1091-1096.
Jhi JW, Sung KC, Oliver YPH, Chih HY and Jia YF (2006). Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J. Control. Release. 115: 140-149.
Kandadi P, Muzammil AS, Surendar G and Kishan V (2011). Brain specific delivery of pegylated indinavir submicron lipid emulsions. Eur. J. Pharm. Sci. 42(4): 423-432.
Margo P, Zanella I, Pescarolo M, Castelli F and Quiros-Roldan E (2020). Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. Biomed. J. https://doi.org/ 10.1016/j.bj.2020.11.005.
Morissette SL, Stephen S, Douglas L, Michael JC and Orn A (2003). Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc. Natl. Acad. Sci. 100(5): 2180-2184.
Müller RH, Jacobs C and Kayser O (2001). Nanosuspensions as particulate drug for mutations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47: 3-19.
Müller RH, Becker R, Kruss B and Peters K (1998). Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution. US Patent, No. 5858410.
Nagaraj K, Narendar D and Kishan V (2017). Development of olmesartan medoxomil optimized nanosuspension using Box-Behnken design to improve oral bioavailability. Drug Dev. Ind. Pharm.43(7): 1186-1196.
Narendar Dand Kishan V (2016). Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharma-cokinetic and pharmacodynamic evaluation. Drug Deliv. 23(2): 395-404.
Patravale VB, Date AA and Kulkarni RM (2004). Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56: 827-840.
Porras M, Solans C, Gonzalez C, Martinez A, Guinart A and Gutierrez JM (2004). Studies of formation of w/o nanoemulsions. Colloids. Surf: A Physicochem. Eng. Asp. 249: 115-118.
Pouton CW (2000). Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-micro-emulsifying drug delivery systems. Eur. J. Pharm. 11: S93-S98.
Prasad N and Keerthana C (2012). Effects of ritonavir on the pharmacokinetics and pharmacodynamics of pioglitazone in normal and diabetic rats. J. Pharm. Res. 5(2): 958-962.
Rabinow BE (2004). Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3: 785 -796.
Sachin KS, Yogyata V, Monica G, Sibasis B, Varun G and Narendra KP (2016). Nanosuspension: Principles, Perspectives and Practices. Cur. Drug Deliv. 13(8): 1222-1246.
Sruthi Y (2011). Preparation and characterization of submicron emulsions of ritonavir for brain specific delivery. Masters thesis, Kakatiya University.
Sinha S, Mushir A, Sanjula B, Alka A, Anil K and Javed A (2010). Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech. 11(2): 518-27.
Suman T, Muzammil AS, Ramesh B and Kishan V (2014). Development and in vivo evaluation of cefdinr nanosuspension for improved oral bioavailability. Int. J. Pharm. Sci. Nanotech. 7(3): 2553-2560.
Swapnil K, Vasif A, Yogendra N, Anup N, UshaY and Nayak (2018). Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting. J. Drug Deliv. Sci. Technol. 44: 181-189.
Tiwari SB and Amiji MM (2006). Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J. Nanosci. Nanotechnol. 6: 3215-3221.
Xiaohui P, Jin S, Mo L and Zhonggui H (2009). Formulation of Nanosuspensions as a new approach for the delivery of poorly soluble drugs. Curr. Nanosci. 5: 417-427.
